Management of painful diabetic neuropathy: What is new or in the pipeline for 2007?

Current Diabetes Reports

Volumn 7, Issue 6, 2007, Pages 409-415

  Ziegler, Dan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUPHENAZINE; GABAPENTIN; HARKOSERIDE; IMIPRAMINE; INSULIN; LAMOTRIGINE; NARCOTIC ANALGESIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; ORAL ANTIDIABETIC AGENT; OXCARBAZEPINE; OXYCODONE; PLACEBO; PREGABALIN; RANIRESTAT; RUBOXISTAURIN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADD ON THERAPY; APPETITE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET THERAPY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAXIMUM TOLERATED DOSE; MORBIDITY; MORTALITY; NAUSEA; NEUROPATHIC PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PHYSIOTHERAPY; POLYNEUROPATHY; REVIEW; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; WEIGHT GAIN; XEROSTOMIA;

DIABETIC NEUROPATHIES; HUMANS; POLYNEUROPATHIES;

EID: 37349027587     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0068-5     Document Type: Review

References (48)

1. Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement [no authors tisted]. Diabetes Care 1988, 11:592-597.
2. Sima AAF, Thomas PK, Ishii D, Vinik A: Diabetic neuropathies. Diabetologia 1997,40:B74-B77.
3. Shaw JE, Zimmet PZ, Gries FA, Ziegler D: Epidemiology of Diabetic Neuropathy. In Textbook of Diabetic Neuropathy. Edited by Gries FA, Cameron NE, Low PA, Ziegler D. Stuttgart, NY: Thieme Medical Publishers; 2003:64-82.
4. Forsblom CM, Sane T, Groop PH, et al.: Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998, 4:1253-1262.
5. Coppini DV, Bowtell PA, Weng C, et al.: Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000, 53:519-523.
6. Abbott CA, Vileikyte L, Williamson S, et al.: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998, 21:1071-1075.
7. Daousi C, MacFarlane IA, Woodward A, et al.: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004, 21:976-982.
8. Davies M, Brophy S, Williams R, Taylor A: The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006, 29:1518-1522.
9. Galer BS, Gianas A, Jensen MP: Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
10. Benbow SJ, Chan AW, Bowsher D, et al.: A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1993, 11:17-21.
11. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
12. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973-1988.
13. Ziegler D: Glycemic control. In Textbook of Diabetic Neuropathy. Edited by Gries FA, Cameron NE, Low PA, Ziegler D. Stuttgart, NY: Thieme Medical Publishers; 2003:91-96.
14. Martin CL, Albers J, Herman WH, et al.: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340-344.
15. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [no authors listed]. Diabetes 1996, 45:1289-1298.
16. Ziegler D, Nowak H, Kempler P, et al.: Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med 2004, 21:114-121.
17. Ziegler D: Thioctic acid for patients with symptomatic diabetic neuropathy. A critical review. Treat Endocrinol 2004, 3:1-17.
18. Ziegler D, Ametov A, Barmov A, et al.: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29:2365-2370.
19. Vinik AI, Bril V, Kempler P, et al.: Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005, 27:1164-1180.
20. Bril V, Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006, 29:68-72.
21. Ekberg K, Brismar T, Johansson BL, et al.: C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007, 30:71-76.
22. Boulton AJ, Vinik AI, Arezzo JC, et al.: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
23. Attal N, Cruccu G, Haanpää M, et al.: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13:1153-1169.
24. Moulin DE, Clark AJ, Gilron I, et al.: Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12:13-21.
25. Finnerup NB, Otto M, McQuay HJ, et al.: Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118:289-305.
26. Finnerup NB, Jensen TS: Mechanisms of disease: mechanism-based classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol 2006, 2:107-115.
27. Jensen TS, Backonja MM, Hernandez Jimenez S, et al.: New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006, 3:108-119.
28. Goldstein DJ, Lu Y, Detke MJ, et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109-118.
29. Raskin J, Pritchett YL, Wang F, et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6:346-356.
30. Wernicke JF, Pritchett YL, D'Souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411-1420.
31. Ziegler D, Pritchett YL, Wang F, et al.: Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007, 30:664-669.
32. Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998, 280:1831-1836.
33. Griesing T, Freeman R, Rosenstock J, et al.: Efficacy, safety, and tolerability of pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials. Diabetologia 2005, 48(suppl 1):A351.
34. Dogra S, Beydoun S, Mazzola J, et al.: Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005, 9:543-554.
35. Thienel U, Neto W, Schwabe SK, et al.: Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004, 110:221-231.
36. Vinik AI, Tuchman M, Safirstein B, et al.: Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007, 128:169-179.
37. Beyreuther BK, Freitag J, Heers C, et al.: Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
38. Rauck RL, Shaibani A, Biton V, et al.: Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23:150-158.
39. Watson CP, Moulin D, Watt-Watson J, et al.: Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
40. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003, 60:927-934.
41. Gilron I, Bailey JM, Tu D, et al.: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324-1334.
42. Portenoy RK, Farrar JT, Backonja MM, et al.: Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 2007, 23:287-299.
43. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo -controlled study. Clin Ther 2007, 29:588-601.
44. Reichstein L, Labrenz S, Ziegler D, Martin S: Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005, 48:824-828.
45. Bosi E, Conti M, Vermigli C, et al.: Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005, 48:817-823.
46. Powell MW, Carnegie DH, Burke TJ: Reversal of diabetic peripheral neuropathy with phototherapy (MIRETM) decreases falls and the fear of falling and improves activities of daily living in seniors. Age Ageing 2006, 35:11-16.
47. Clifft JK, Kasser RJ, Newton TS, Bush AJ: The effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy: a double-blind, placebo-controlled study. Diabetes Care 2005, 28:2896-2900.
48. Gilron I, Coderre TJ: Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007, 12:113-126.